4 completed. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
Follow Progressive Supranuclear Palsy (PSP): new trials by email Literature Review of Progressive Supranuclear Palsy (PSP) trials Research Report on Progressive Supranuclear Palsy (PSP)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of NIO752 in Progressive Supranuclear Palsy antisense oligonucleotide, placebo - Progressive Supranuclear Palsy (PSP) | Phase 1 | Completed | Novartis Pharmaceuticals | 59 | 2021-02-16 | 2025-12-24 |
| Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104 ABBV-8E12 - Progressive Supranuclear Palsy (PSP) | Phase 1 | Completed | AbbVie | 3 | 2018-04-17 | 2019-12-03 |
| Safety Study of TPI-287 to Treat CBS and PSP TPI 287 2 mg/m2, TPI-287 20 mg/m2, Placebo - Primary Four Repeat Tauopathies (4RT), Corticobasal Syndrome (CBS) | Phase 1 | Completed | University of California, San Francisco | 44 | 2014-05-01 | 2020-04-15 |
| Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects [18F]T807 ([18F]MNI-777) - Alzheimer's Disease (AD), Parkinson's Disease (PD) | Phase 1 | Completed | Molecular NeuroImaging | 16 | 2014-02-01 | 2016-12-16 |
Supranuclear Palsy, Progressive (4) · Pick Disease of the Brain (2) · Alzheimer Disease (1) · Chronic Traumatic Encephalopathy (1) · Color Vision Defects (1) · Corticobasal Degeneration (1) · Parkinson Disease (1) · Tauopathies (1)
Basal Ganglia Diseases (4) · Brain Diseases (4) · Central Nervous System Diseases (4) · Cranial Nerve Diseases (4) · Eye Diseases (4) · Movement Disorders (4) · Nervous System Diseases (4) · Neurodegenerative Diseases (4) · Neurologic Manifestations (4) · Ocular Motility Disorders (4) · Ophthalmoplegia (4) · Paralysis (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Tauopathies (3)
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · Oligonucleotides, Antisense (1) · TPI-287 (1) · florbetapir (1) · tilavonemab (1)
AbbVie (1) · Molecular NeuroImaging (1) · Novartis Pharmaceuticals (1) · University of California, San Francisco (1)
United States (4) · Canada (1) · Germany (1) · United Kingdom (1)
Adam Boxer, MD, PhD (1) · Danna Jennings, MD (1)